The U.S. Food and Drug Administration has given its approval of ClearVoice by Advanced Bionics of Valencia for use in adults, the company announced Monday.

ClearVoice, first and only speech enhancement technology on the market, has already been approved for use in in Europe, Asia and Canada. Advanced Bionics, a global leader in cochlear implants and a subsidiary of Switzerland’s Sonova Group, said it will begin making the new technology available in the United States over the next few weeks as it trains clinicians.

Using Advanced Bionics’ proprietary HiRes Fidelity 120 technology, ClearVoice is designed to provide recipients with improved speech clarity in noisy settings; enhanced lyric understanding for music enjoyment; easier, more effortless listening in real-world settings; and outstanding hearing from morning to evening with no adjustments needed.

“ClearVoice has been designed to automatically analyze and adapt to each listening situation encountered throughout the day, separating the distracting noises from speech so that communication can be a truly effortless experience,” according to a company statement. “The technology was developed to help recipients communicate clearly and confidently in a variety of challenging listening situations, including restaurants, cars and classrooms — without ever needing to change a program or make an adjustment to their sound processor.”

ClearVoice will be available for recipients with HiRes 90K and CII implants who use a Harmony or Neptune sound processor. The manufacturer says recipients should wait until April 9 to begin scheduling appointments.